These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18448619)

  • 21. EIAV envelope diversity: shaping viral persistence and encumbering vaccine efficacy.
    Craigo JK; Montelaro RC
    Curr HIV Res; 2010 Jan; 8(1):81-6. PubMed ID: 20210783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy.
    Craigo JK; Li F; Steckbeck JD; Durkin S; Howe L; Cook SJ; Issel C; Montelaro RC
    J Virol; 2005 Mar; 79(5):2666-77. PubMed ID: 15708986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus.
    Issel CJ; Horohov DW; Lea DF; Adams WV; Hagius SD; McManus JM; Allison AC; Montelaro RC
    J Virol; 1992 Jun; 66(6):3398-408. PubMed ID: 1316455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specificity of serum neutralizing antibodies induced by transient immune suppression of inapparent carrier ponies infected with a neutralization-resistant equine infectious anemia virus envelope strain.
    Howe L; Craigo JK; Issel CJ; Montelaro RC
    J Gen Virol; 2005 Jan; 86(Pt 1):139-149. PubMed ID: 15604441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple RNA splicing and the presence of cryptic RNA splice donor and acceptor sites may contribute to low expression levels and poor immunogenicity of potential DNA vaccines containing the env gene of equine infectious anemia virus (EIAV).
    Zhou W; Cook RF; Cook SJ; Hammond SA; Rushlow K; Ghabrial NN; Berger SL; Montelaro RC; Issel CJ
    Vet Microbiol; 2002 Aug; 88(2):127-51. PubMed ID: 12135633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic immunization with codon-optimized equine infectious anemia virus (EIAV) surface unit (SU) envelope protein gene sequences stimulates immune responses in ponies.
    Cook RF; Cook SJ; Bolin PS; Howe LJ; Zhou W; Montelaro RC; Issel CJ
    Vet Microbiol; 2005 Jun; 108(1-2):23-37. PubMed ID: 15885929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid emergence of novel antigenic and genetic variants of equine infectious anemia virus during persistent infection.
    Salinovich O; Payne SL; Montelaro RC; Hussain KA; Issel CJ; Schnorr KL
    J Virol; 1986 Jan; 57(1):71-80. PubMed ID: 3001367
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Lin Y; Wang XF; Wang Y; Du C; Ren H; Liu C; Zhu D; Chen J; Na L; Liu D; Yang Z; Wang X
    Emerg Microbes Infect; 2020 Dec; 9(1):1309-1320. PubMed ID: 32525460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The determination of in vivo envelope-specific cell-mediated immune responses in equine infectious anemia virus-infected ponies.
    Liu C; Cook FR; Cook SJ; Craigo JK; Even DL; Issel CJ; Montelaro RC; Horohov DW
    Vet Immunol Immunopathol; 2012 Aug; 148(3-4):302-10. PubMed ID: 22795699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An attenuated EIAV vaccine strain induces significantly different immune responses from its pathogenic parental strain although with similar in vivo replication pattern.
    Lin YZ; Shen RX; Zhu ZY; Deng XL; Cao XZ; Wang XF; Ma J; Jiang CG; Zhao LP; Lv XL; Shao YM; Zhou JH
    Antiviral Res; 2011 Nov; 92(2):292-304. PubMed ID: 21893100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity.
    Craigo JK; Montelaro RC
    Viruses; 2013 Dec; 5(12):2963-76. PubMed ID: 24316675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antigenic mapping of the envelope proteins of equine infectious anemia virus: identification of a neutralization domain and a conserved region on glycoprotein 90.
    Hussain KA; Issel CJ; Schnorr KL; Rwambo PM; West M; Montelaro RC
    Arch Virol; 1988; 98(3-4):213-24. PubMed ID: 2450529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor necrosis factor-alpha production and disease severity after immunization with enriched major core protein (p26) and/or infection with equine infectious anemia virus.
    Costa LR; Santos IK; Issel CJ; Montelaro RC
    Vet Immunol Immunopathol; 1997 Jun; 57(1-2):33-47. PubMed ID: 9239836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of EIAV immunogenicity during persistent infections: humoral responses and antigen targets.
    Montelaro RC; Ball JM; Issel CJ
    Dev Biol Stand; 1990; 72():19-30. PubMed ID: 1704323
    [No Abstract]   [Full Text] [Related]  

  • 35. Long terminal repeats are not the sole determinants of virulence for equine infectious anemia virus.
    Tu YB; Zhou T; Yuan XF; Qiu HJ; Xue F; Sun CQ; Wang L; Wu DL; Peng JM; Kong XG; Tong GZ
    Arch Virol; 2007 Jan; 152(1):209-18. PubMed ID: 16932982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serological method using recombinant S2 protein to differentiate equine infectious anemia virus (EIAV)-infected and EIAV-vaccinated horses.
    Jin S; Issel CJ; Montelaro RC
    Clin Diagn Lab Immunol; 2004 Nov; 11(6):1120-9. PubMed ID: 15539516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horses.
    Taylor SD; Leib SR; Carpenter S; Mealey RH
    J Virol; 2010 Jul; 84(13):6536-48. PubMed ID: 20392850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein.
    Wang SZ; Rushlow KE; Issel CJ; Cook RF; Cook SJ; Raabe ML; Chong YH; Costa L; Montelaro RC
    Virology; 1994 Feb; 199(1):247-51. PubMed ID: 8116252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune selection of equine infectious anemia virus env variants during the long-term inapparent stage of disease.
    Sponseller BA; Sparks WO; Wannemuehler Y; Li Y; Antons AK; Oaks JL; Carpenter S
    Virology; 2007 Jun; 363(1):156-65. PubMed ID: 17328936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transient suppression of equine immune responses by equine infectious anemia virus (EIAV).
    Newman MJ; Issel CJ; Truax RE; Powell MD; Horohov DW; Montelaro RC
    Virology; 1991 Sep; 184(1):55-66. PubMed ID: 1651604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.